CME Presentations

Management of HER2+ mCRC



  • Leonard Saltz, MD

    Leonard Saltz, MD

    Leonard Saltz, MD

    Professor of Medicine

    Leonard B. Saltz, MD is a gastrointestinal medical oncologist and professor of medicine at Weill Cornell Medical College. Dr. Saltz is also an attending physician at Memorial Sloan- Kettering Cancer Center (MSKCC), where he serves as executive director for clinical value and sustainability. He has led numerous clinical and translational trials at MSKCC and served as principal investigator on several multicenter national and international clinical trials. He has authored or co-authored more than 300 peer-reviewed articles, as well as numerous reviews, books, book chapters, and editorials. He has also written and spoken extensively about rising costs and the declining relative value of many of the newer anticancer therapies, and the role these high-cost drugs play in exacerbating disparities in cancer care.
  • Christopher Lieu, MD, FASCO

    Christopher Lieu, MD, FASCO

    Christopher Lieu, MD, FASCO

    Associate Director for Clinical Research

    Christopher Lieu, MD is an associate professor in the Division of Medical Oncology, and associate director for clinical research at the University of Colorado School of Medicine in Aurora. Dr. Lieu completed his fellowship training in medical oncology at the University of Texas MD Anderson Cancer Center in Houston and served as the chief medical oncology fellow. He currently serves as associate director for clinical research and director of GI medical oncology at the University of Colorado Cancer Center, as well as the vice-chair of the National Cancer Institute Colon Cancer Task Force. He serves on the FDA Oncologic Drugs Advisory Committee and National Comprehensive Cancer Network (NCCN) Panel for Neuroendocrine Cancers. His research interests include resistance mechanisms to targeted therapy in GI cancers and novel therapeutic strategies to more effectively treat and prevent colorectal cancer in young adults.

CME Information

Global LogoPQH Logo

State‐of‐the‐Art Approaches for Biomarker Testing and Management of HER2+ mCRC

Jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC, in collaboration with the Colorectal Cancer Alliance (CCA).


This activity is supported by an independent medical education grant from Seagen.


Friday, December 8th, 2023 from 12pm-1pmET


The educational design of this activity addresses the needs of – GI oncologists, medical oncologists, physician assistants, pathologists, oncology nurses, and other HCPs involved in the care of patients with colorectal cancer


Colorectal cancer (CRC) is the third most common cancer in men and women and the second leading cause of cancer death in the US. With new therapeutic targets, such as HER2, emerging in mCRC, it can be difficult to stay up to date with the most recent literature, recommendations, and best practices regarding when to test for HER2 in CRC, which test to use, and when to use anti‐HER2 treatment. In addition, new FDA‐approved indications for regimens in HER2+ mCRC require appropriate application of the evidence on anti‐HER2 agents.

Join a panel of experts to discuss the optimization of HER2+ mCRC therapy and HER2 testing benefits and limitations. The panel will also discuss variations in testing and the need to stay up to date with the literature as new and emerging clinical trials continue to change the landscape of HER2+ mCRC treatment.


After completing this activity, the participant should be better able to:
  • Apply guideline‐based recommendations for sequencing and selecting appropriate testing modalities for HER2 in mCRC, based on the clinical situation
  • Discuss the current anti‐HER2 treatments available for use, appropriate sequencing of therapy in HER2+ mCRC, and monitoring and management of adverse effects Implement evidence-based interventions to increase CRC screening rates, especially in younger adults and underserved populations


JointlyAccreditedProvider Logo In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


PACE designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 60 minutes to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a score of 75% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Name of Faculty or Presenter Conflicts of Interest
Leonard B. Saltz, MD
Attending Physician and Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
Consultant/Advisor/Speaker: Genor Biopharma Ltd
Christopher Lieu, MD, FASCO
Associate Professor
Associate Director for Clinical Research
University of Colorado Cancer Center
Consultant/Advisor/Speaker: Pfizer
Grant/Research Support: Merck, Genentech

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support:

For additional information about the accreditation of this activity, please visit

Technical Support:

For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at